No Data
No Data
Market Mover | Mesoblast Shares Hit Four-Year High After Receiving US FDA Approval for Mesenchymal Stromal Cell Therapy
3 ASX 300 Shares Smashing New Highs While the Market Dives
Why Champion Iron, EBR Systems, Mesoblast, and Patriot Battery Metals Shares Are Surging Today
Express News | Mesoblast Ltd(MSB.AU) soared 33.59% to AUD$2.645 with a turnover of AUD$50.28 million.
Mesoblast ADRs Rise 22%, FDA Approves Ryoncil for Pediatric Patients -- Update
Mesoblast Share Price Rockets 30% on Big US FDA News